Therapeutic antibodies represent an increasing share of new drug approvals and a current global market well in excess of $100B. Their research and development, however, is fraught with significant risks and many promising candidates fail to reach the clinic due to inefficient workflows and insufficient preclinical evaluation.

Biocytogen’s state-of-the-art screening technologies and humanized antibody mouse platforms de-risk the entire enterprise of antibody drug discovery and development. Join us to learn how to generate higher quality hits, and perform high-throughput screening of top candidates.

Among the topics we will discuss are:

• The advantages of high-throughput single B cell screening technologies (the Beacon® Optofluidics System and FACS) for antibody discovery.
• Therapeutic discovery using our fully human antibody mice to generate antibodies with high affinity and broad diversity.

Event Agenda:

8:30 – Coffee Reception

9:00 – Presentation

9:30 – Q&A Session

 

Hosted by

Li Hui, M.D., Ph.D.

Director, Antibody Discovery & RenMice™ Licensing, Biocytogen Boston

Dr. Hui has more than a decade of experience in the antibody discovery field. Before joining Biocytogen, she was a Senior Principal Scientist and team leader at ABclonal Technology and, prior to that, a Senior Development Scientist in monoclonal antibody discovery at Cell Signaling Technology. Dr. Hui completed her medical training in China, earned a Ph.D. in Molecular Cell Biology at City University of New York, and completed postdoctoral training at the Novartis Institutes for Biomedical Research.

John Charpentier, Ph.D.

Scientific Content Specialist, Biocytogen Boston

A T cell immunologist by training, Dr. Charpentier joined Biocytogen in 2021 as a business development manager. Prior to that he earned a Ph.D. in immunology from the University of Michigan and trained extensively in science communication. A native of New England, Dr. Charpentier is thrilled to be home, now working in a content and communications role for the company.